Rocket Pharmaceuticals, Inc.

RCKT Nasdaq SEC CIK 1281895
Follow Rocket Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$49.2M +2.2% vs same quarter last year
EPS, diluted −$0.43 +4.4% vs same quarter last year
Operating cash flow −$39.1M +22.5% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income13 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$223.1M
FY24$0−$258.7M
FY23$0−$245.6M
FY22$0−$221.9M
FY21$0−$169.1M
FY20$0−$139.7M
FY19$0−$77.3M
FY18$0−$74.5M
FY17$0−$19.6M
FY16$0−$7.6M
FY15-−$68M
FY14-−$9.5M
FY13--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$190.5M
FY24−$215.6M
FY23−$211.4M
FY22−$186.5M
FY21−$128.8M
FY20−$95.2M
FY19−$87.9M
FY18−$55.2M
FY17−$16.7M
FY16−$5.8M
FY15−$17.8M
FY14-
FY13-
Returned to shareholdersDividends paid and shares bought back
$0$20K$40K$60K$80KFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22-
FY21$0
FY20$72K
FY19$0
FY18$0
FY17$0
FY16$0
FY15-
FY14-
FY13-